2 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Approved WMOCompleted
Within the proposed study design it is possible to answer more study questions within the same population and within the same timeframe without adding much burden to the study participants. measurements and analyses will be performed both during a…